Sanofi To Acquire Blueprint Medicines In $9.5 Bln Deal

Sanofi (SNYNF) will acquire Blueprint Medicines Corp. (BPMC) for $9.5 billion, including contingent value rights, to bolster its immunology pipeline with Ayvakit/Ayvakyt and Blueprint's established presence among allergists and immunologists. Sanofi will pay $129 per share in cash, a 33% premium over the May 30, 2025 closing price, and expects the deal to close in Q3 2025, becoming accretive to gross margin and EPS after 2026 without significantly impacting 2025 financial guidance.

Analysis

Sanofi has announced a definitive agreement to acquire Blueprint Medicines Corp. for approximately $9.5 billion on a fully diluted basis, a transaction structured to significantly bolster Sanofi's immunology franchise. The deal consideration includes $129.00 per share in cash, translating to an equity value of approximately $9.1 billion, and one non-tradeable contingent value right (CVR) per Blueprint share, which offers two potential milestone payments totaling $6 ($2 and $4) tied to the future development and regulatory success of BLU-808. This offer represents a substantial premium of approximately 33% over Blueprint's closing price on May 30, 2025, and approximately 40% over its 30-trading day volume-weighted average price. Key strategic assets being acquired include Ayvakit/Ayvakyt (avapritinib), an approved rare immunology disease medicine, a promising immunology pipeline, and Blueprint's established commercial presence with specialists. Sanofi anticipates the acquisition, expected to close in the third quarter of 2025 pending customary conditions and not subject to financing, will be immediately accretive to its gross margin and will enhance business operating income and earnings per share after 2026, without significantly impacting its 2025 financial guidance.

Key Decisions for Investors

• Blueprint Medicines shareholders should assess the $129 per share cash offer, which provides a significant premium and immediate liquidity, while also considering the potential long-term value of the CVRs linked to BLU-808 milestones.
• Sanofi investors should recognize this acquisition as a strategic move to strengthen its immunology pipeline with an approved product and future growth drivers, noting the expected accretion to gross margin immediately and to operating income and EPS after 2026, while monitoring the successful integration and development of acquired assets.
• Investors focused on the biotechnology sector should observe this transaction as an indicator of continued M&A activity and strong valuations for companies with approved rare disease drugs and promising clinical pipelines, particularly within the immunology space.